About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.
Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.AmericasMedicines.com
www.Facebook.com/PhRMA
www.X.com/PhRMA
In October 2023, the World Health Organization (WHO) released a draft of the WHO Pandemic Agreement, which seeks to negotiate a global consensus on how best to strengthen pandemic prevention, preparedness and response (PPPR). As drafted, the negotiating text included both positive and negative implications for global health and biopharmaceutical innovation. To achieve its goal of ensuring that the world is better prepared for future pandemics, it is critical that the PPPR agreement does not undermine biopharmaceutical innovation and collaboration.
WHO Pandemic Agreement: Pros and Cons for U.S. Innovation image
Fact Sheet
International
WHO Pandemic Agreement: Pros and Cons for U.S. Innovation
WHO Pandemic Agreement: Pros and Cons for U.S. Innovation image